Critical Issues in Head and Neck Oncology

lt;p>Prof. Jan B. Vermorken started his medical training in 1961, graduated in 1970 from the University of Amsterdam, the Netherlands, and became a board-certified specialist in internal medicine in 1975. Since that time he has worked in the field of Medical Oncology and was officially registered as a Medical Oncologist in the Netherlands in 1992. He received his PhD in Medical Sciences in 1986 from the Vrije Universiteit in Amsterdam. From May 1997 until October 1, 2009, he was appointed Professor of Oncology at the University of Antwerp (UA), and head of the Department of Medical Oncology at the University Hospital Antwerp (UZA), in Edegem, Belgium. After his retirement he remains connected to both University (Emeritus Professor) and University Hospital (consultant). His main fields of interest are head and neck oncology and gynecologic oncology. He chaired both the Head and Neck Cancer Group (2006-2009) and the Gynecologic Cancer Group (1983-1989) of the European Organization for the Research and Treatment of cancer (EORTC). He was founding chair of the Gynecologic Cancer InterGroup (GCIG: 1997-2003) and strongly involved in establishing the Head and Neck Cancer International Group (HNCIG) in 2015. He devotes a large part of his time to teaching, professional training, and continuing medical education.

Professor Vermorken is member of various scientific societies, member of several editorial boards of International journals, reviewer of multiple cancer journals and author or co-author of more than 700 publications. He was Editor-in-Chief of Annals of Oncology from 2009 to 2014 and is chief editor of the head and neck cancer section of The Oncologist (since 2003), and the head and neck section of Frontiers in Oncology (since 2015), is editorial chair of ONCOhemato (multidisciplinary journal; since 2007) in Belgium and chairs Oncotherapie (an internet platform) in The Netherlands (since 2007). He received the ESMO award in 2007 and on March 1, 2013 he received the title of Commander in the Order of Leopold for his contributions to oncology.

Jean-Pascal Machiels MD, PhD, is head of department of medical oncology and director of the Institut Roi Albert II Cancer centre, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels Belgium. He trained at Université Catholique de Louvain, Brussels, Belgium, where he gained his MD in 1993 and his PhD in 2001 and at Johns Hopkins School of Medicine, Baltimore USA, where he was a Fellow in Medical Oncology from 1998 until 2000,. His main interests include Head and Neck cancer, and phase 1 clinical trials. He has published more than two hundred papers reporting on clinical trials and translational research.

Prof. Volker Budach. MD is Head of the Depts. for Radiation Oncology at the Charité University Medicine Berlin. He became a board certified radiation oncologist at the University of Essen in 1985 and was appointed as full professor and chair of the Dept. for Radiation Oncology at the Charité University Clinics in 1993. He was board member and treasurer of the ESTRO during 1996 and 2004 and chairman of the EORTC-Radiooncology Group during 2000-2003, followed by the chairmanship o^ 330 peer reviewed publications cited in Pubmed

Professor C. René Leemans, MD, PhD is chair of the Department of Otolaryngology Head and Neck Surgery at the Amsterdam University Medical Centres, VUmc, Amsterdam. He is Director of the Advanced Fellowship Program in Head and Neck Surgery and Oncology at the VU University Medical Centre Amsterdam. His special interests include head and neck oncology, reconstructive and microvascular surgery, and basic research. René Leemans has made a sustained and internationally recognised contribution to cancer care and research in the field of head and neck oncology over the past decades. His scientific standing has been recognised by election as Pres

Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC).- Promising biomarkers for early diagnosis and prognosis prediction in HNS.- Biomarkers to predict radiotherapy toxicity.- Biomarkers for hypoxia, HPVness and proliferation from imaging perspective.- Mechanism of cetuximab resistance and how to overcome it.- The role of liquid biopsy for monitoring disease evolution.- NK cells in immunotherapy: how important are they?.- Biomarkers for immune modulatory treatment in HNSCC.- Primary disease (1).- Novel approaches in surgical management of HNSCC.- The surgical approach to elderly patients with HNSCC .- The nonsurgical approach to locoregionally advanced HNSCC.- High-dose three-weekly or low-dose weekly cisplatin during radiation, what to prefer?.- Primary disease (2).- Where and when to use induction chemotherapy?.- Prognostic role of p16/HPV in non-oropharyngeal head and neck cancer.- Is there a role for neoadjuvant targeted and immunotherapies?.- Is there a role for adjuvant targeted and immunotherapies? .- Optimal supportive measures during primary treatment.- Precision Medicine in head and neck cancer: myth or reality.- Recurrent and / or metastatic disease.- Salvage surgery:  candidates, safe reconstruction, and results?.-  Re-irradiation for local relapses or second primaries: when and how?.- New promising targeted agents in first and second-line settings.- Update of immune therapies in recurrent/metastatic HNSCC.- Special Issue.- Patients with rare head neck cancers: do they need a different approach? .-Nasopharynx cancer.- New epidemiological aspects.- New developments in the management of nasopharyngeal carcinoma.- New drugs for recurrent/metastatic nasopharynx cancer.

"Each chapter is enhanced with coloured figures and diagrams and liberally supported by published references ... . This publication is recommended to all clinicians involved in patient management with head and neck cancer as a 'source of knowledge' on the modern and future treatment options of this disease." (PJ Bradley, The Journal of Laryngology & Otology, June 2, 2021)

“Each chapter is enhanced with coloured figures and diagrams and liberally supported by published references … . This publication is recommended to all clinicians involved in patient management with head and neck cancer as a ‘source of knowledge’ on the modern and future treatment options of this disease.” (PJ Bradley, The Journal of Laryngology & Otology, June 2, 2021)